Current antidepressant treatments for Major Depressive Disorder (MDD) have limited efficacy and effectiveness. While measurement of response and remission is typically based on overall symptom reduction, the utilization of a dimensional approach, involving mood, cognitive and neurovegetative symptoms, may be more effective in predicting response to different antidepressant classes. In addition to these dimensions, evaluation of function is increasingly recognized as an important patient indicator of antidepressant efficacy. This paper reviews the efficacy of second generation antidepressant classes across the proposed symptom dimensions, and explores the potential benefits of agomelatine. While further research is required, agomelatine generally performed well in the mood dimension including measures of depressed mood, anxiety and anhedonia without inducing emotional blunting. Improvements in daytime alertness and clear thinking, combined with measures of subjective and objective sleep differentiate agomelatine from other currently available antidepressants, and likely contribute to favourable functional outcomes.
Agosti, V., Stewart, J.W. (1998). Social functioning and residual symptomatology among outpatients who responded to treatment and recovered from major depression. Journal of Affective Disorders, 47, 207-210. doi:10.1016/S0165-0327(97)00119-5
Amado-Boccara, I., Gougoulis, N., Poirier, L.M., Galinowski, A., & Loo, H. (1992). Effects of antidepressants on cognitive functions: A review. Neuroscience & Biobehavioral Reviews, 19, 479-493.doi:10.1016/0149-7634(94)00068-C
Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amosse, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J. P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Renard, P., Delagrange, P., & Boutin, J.A. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. NaunynSchmiedeberg’s Arch Pharmacol, 367, 553-561. doi:10.1007/s00210-003-0751-2
Austin, M., Mitchell, P., & Goodwin, G. ( 2001). Cognitive deficits in depression: Possible implications for functional neuropathology. Brit- ish Journal of Psychiatry, 178, 200-206. doi:10.1192/bjp.178.3.200
Blier, P., & Blondeau, C. (2011). Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depres- sive disorder. Journal of Affective Disorders, 128, S3-S10.doi:10.1016/S0165-0327(11)70003-9
Bondareff, W., Alpert, M., Friedhoff, A., Richter, E., Clary, C., & Batzar, E. (2000). Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. American Journal of Psychiatry, 157, 729-36. doi:10.1176/appi.ajp.157.5.729
Brodbeck, J., Abbott, R.A., Goodyer, I.M., & Croudace, T.J. (2011). General and specific components of depression and anxiety in an adolescent population. BMC Psychiatry, 11, 191.doi:10.1186/1471-244X-11-191
Cipriani, A., La Ferla, T., Furukawa, T.A., Signoretti, A., Nakagawa, A., Churchill, R., & Barbui, C. (2010). Sertraline versus other anti- depressive agents for depression. Cochrane Database of Systematic Reviews, 1.
Conradi, H. J., Ormel, J., & de Jonge, P. (2010). Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychological Medicine, 8, 1-10.
Corruble, E., Belaidi, C., & Goodwin, G. (2011). P02-24-Agomelatine versus escitalopram in major depressive disorders: A randomized double-blind, long term study focusing on sleep satisfaction and emotional blunting. European Psychiatry, 26, 619. doi:10.1016/S0924-9338(11)72325-2
Cunningham, L., Borison, R., Carman, J., Chouinard, G., Crowder, J.E., Diamond, B.I., Fischer, D.E., & Hearst, E.(1994). A comparison of venlafaxine, trazodone, and placebo in major depression. Journal of Clinical Psychopharmacology, 15, 30-40.
Di Giannantonio, M., Di Iorio, G., Guglielmo, R., De Berardis, D., Conti, C.M., Acciavatti, T., Cornelio, M., & Martinotti, G. (2011). Major depressive disorder, anhedonia and agomelatine: An open-la- bel study. Journal of Biological Regulators & Homeostatic Agents, 25, 109-114
Demyttenaere, K. (2011). Agomelatine: A narrative review. European Neuropsychopharmacology, 21, S703-S709. doi:10.1016/j.euroneuro.2011.07.004
Doraswaimy, P., Krishnan, K., Oxman, T., Jenkyn, L.R., Coffey, D.J., Burt, T., & Clary, C.M. (2003). Does antidepressant therapy improve cognition in elderly depressed patients? Journals of Gerontology, 12, 1137-1144.
Dunner, D.L., & Dunbar, G.C. (1992). Optimal dose for paroxetine. Journal of Clinical Psychiatry, 53, 21-26.
Farabaugh, A.H., Bitran, S., Witte, J., Alpert, J., Chuzi, S., Clain, A.J., & Papakostas, G. I. (2010). Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. International Clinical Psychopharmacology, 25, 214-217. doi:10.1097/YIC.0b013e328339fbbd
Fava, M., Rush, A.J., Alpert, J.E., Balasubramani, G.K., Wisniewski, S.R., Carmin, C.N., Biggs, M.M., Zisook, S., Leuchter, A., Howland, R., Warden, D., & Trivedi, M.H. (2008). Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. American Journal of Psychiatry, 165, 342-351. doi:10.1176/appi.ajp.2007.06111868
Fekadu, A., Wooderson, S. C., Rane, L. J., Markopoulou, K., Poon, L., Cleare, A. J. (2011). Long-term impact of residual symptoms in treat- ment-resistant depression. Canadian Journal of Psychiatry, 56, 549-557.
Fossati, P., Amar, G., Raoux, N., Ergis, A., & Alligaire, J. (1999). Executive functioning and verbal memory in young patients with unipolar depression and schizophrenia. Psychiatry Research, 89, 171-187. doi:10.1016/S0165-1781(99)00110-9
Furlan, P., Kallan, M., Ten, T., Pollock, B. G., Katz, I., & Lucki, I. (2001). Cognitive and psychomotor effects of paroxetine and sertr- aline on healthy elderly volunteers. American Journal of Geriatric Psychiatry, 9, 429-437.
Gualtieri, C., & John, L. (2007). Bupropion normalizes cognitive per- formance in patients with depression. Medscape General Medicine, 9, 22.
Hale, A., Corral, R. M., Mencacci, C., Ruiz, J. S., Severo, C. A., & Gentil, V. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, doubleblind study. International Clinical Psychopharmacology, 25, 305- 314. doi:10.1097/YIC.0b013e32833a86aa
Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55. doi:10.1111/j.2044-8341.1959.tb00467.x
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62. doi:10.1136/jnnp.23.1.56
Harmer, C.J., Shelley, N.C., Cowen, P.J., & Goodwin, G.M. (2004). Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepine- phrine reuptake inhibition. American Journal of Psychiatry, 7, 1256- 1263. doi:10.1176/appi.ajp.161.7.1256
Harmer, C.J., de Bodinat, C., Dawson, G.R., Dourish, C.T., Walden- maier, L., Adams, S., Cowen, P.J., & Goodwin, G.M. (2011). Ago- melatine facilitates positive versus negative affective processing in healthy volunteer models. Journal of Psychopharmacology, 25, 1159-1167. doi:10.1177/0269881110376689
Joyce, P.R., Mulder, R.T., McKenzie, J.M., Luty, S.E., & Cloninger, C.R. (2004). Atypical depression, atypical temperament and a dif- ferential antidepressant response to fluoxetine and nortriptyline. De- pression and Anxiety, 19, 180-186. doi:10.1002/da.20001
Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W.J., Montejo, A.L., Smeraldi, E., Rybakowski, J.K., Quera-Salva, M.A., Wirz-Justice, A.M., Picarel-Blanchot, F., & Baylé, F.J. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. Journal of Clinical Psychiatry, 71, 109-120. doi:10.4088/JCP.09m05347blu
Keller, M. B., Lavori, P. W., Friedman, B., Nielsen, E., Endicott, J. et al. (1987). The longitudinal follow-up evaluation: A comprehensive method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry, 44, 540-548. doi:10.1001/archpsyc.1987.01800180050009
Keltner, N. L., McAfee, K. M., & Taylor, C. L. (2002). Mechanisms and treatments of SSRI induced sexual dysfunction. Perspectives in Psy- chiatric Care, 38, 111-116. doi:10.1111/j.1744-6163.2002.tb00665.x
Kendell, R. E. (1975). The role of diagnosis in psychiatry. Oxford: Blackwell Scientific Publications.
Kennedy, S. H., & Emsley, R. (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neu- ropsychopharmacology, 16, 93-100. doi:10.1016/j.euroneuro.2005.09.002
Kennedy, S.H., Rizvi, S., Fulton, K., & Rasmussen, J. (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology, 28, 329-333. doi:10.1097/JCP.0b013e318172b48c
Kennedy, S.H., & Rizvi, S.J. (2009). Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs, 14, 439-453.doi:10.1517/14728210903107751
Kennedy, S.H, & Rizvi, S.J. (2010). Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs, 24, 479-499. doi:10.2165/11534420-000000000-00000
Korszun, A., Moskvina, V., Brewster, S., Craddock, N., Ferrero, F., Gill, M., Jones, I.R., Jones, L.A., Maier, W., Mors, O., Owen, M.J., Preisig, M., Reich, T., Rietschel, M., Farmer, A., & McGuffin, P. (2004). Familiality of symptom dimensions in depression. Archives of General Psychiatry, 61, 468-474. doi:10.1001/archpsyc.61.5.468
Laux, G. (2011). P02-52—The antidepressant efficacy of agomelatine in daily practice: Results of the non-interventional study VIVALDI. European Psychiatry, 26, 647. doi:10.1016/S0924-9338(11)72353-7
Lemoine, P., Guilleminault, C., & Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry, 68, 1723-1732.doi:10.4088/JCP.v68n1112
Liemburg, E., Aleman, A., Bous, J., Hollander, K., & Knegtering, H. (2011). An open randomized pilot trial on the differential effects of aripiprazoleversus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry, 44, 109-113. doi:10.1055/s-0031-1271688
L?o, H., Hale, A., & D’haenen, H. (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) anta- gonist, in the treatment of major depressive disorder: A placebo- controlled dose range study. International Clinical Psychopharmacology, 17, 239-247. doi:10.1097/00004850-200209000-00004
McCabe, C., Mishor, Z., Cowen, P.J., & Harmer, C.J. (2010). Dimi- nished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biological Psychiatry, 67, 439-445. doi:10.1016/j.biopsych.2009.11.001
McKnight, P.E., & Kashdan, T.B. (2009). The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research. Clinical Psychology Review, 29, 243-259. doi:10.1016/j.cpr.2009.01.005
McMakin, D.L, Olino, T.M., Porta, G., Dietz, L.J., Emslie, G., Clarke, G., Wagner, K.D., Asarnow, J.R, Ryan, N.D., Birmaher, B., Sham- seddeen, W., Mayes, T., Kennard, B., Spirito, A., Keller, M., Lynch, F.L., Dickerson, J.F., & Brent, D.A. (2012). Anhedonia predicts poorer recovery among youth with selective serotonin reuptake in- hibitor treatment resistant-depression. Journal of the American Academy of Child and Adolescent Psychiatry, 51, 404-411. doi:10.1016/j.jaac.2012.01.011
Mendels, J., Johnston, R., Mattes, J., & Riesenberg, R. (1993). Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169-174.
Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M., & Cussac, D. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxy-tryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics, 306, 954-964.doi:10.1124/jpet.103.051797
Montejo, A., Majadas, S., Rizvi, S., & Kennedy, S.H. (2011). The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology-Clinical and Experimental, 26, 537-542. doi:10.1002/hup.1243
Montgomery, S.A., & Asberg, A. (1979). A new depression scale designed to be sensitive to change. The British Journal of Psychiatry, 134, 382-389. doi:10.1192/bjp.134.4.382
Montgomery, S.A., & Kasper, S. (2007). Severe depression and anti- depressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology, 22, 283-291. doi:10.1097/YIC.0b013e3280c56b13
Olie, J.P., & Kasper, S. (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major de- pressive disorder. International Journal of Neuropsychopharmacol- ogy, 10, 661-673.
Opbroek, A., Delgado, P.L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F.A., & Manber, R. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5, 147-151. doi:10.1017/S1461145702002870
Ossewaarde, L., Verkes, R.J., Hermans, E.J., Kooijman, S.C., Urner,M., Tendolkar, I., van Wingen, G.A., & Fernandez, G. (2011). Two-week administration of the combined serotonic-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits. Biological Psychiatry, 70, 568-574. doi:10.1016/j.biopsych.2011.03.041
Nierenberg, A.A., & Wright, E.C. (1999). Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry, 60, 7-11.
Novotny, V., & Pecenák, J. (2011). Agomelatine—First results from trial VALID in Slovakia. International Journal of Psychiatry in Clinical Practice, 33-34.
Papakostas, G.I., & Larsen, K. (2011). Testing anxious depression as a predictor and moderator of symptom improvement in major depresssive disorder during treatment with escitalopram. European Archives of Psychiatry and Clinical Neuroscience, 261, 147-156. doi:10.1007/s00406-010-0149-3
Parker, G., Wilhelm, K., Mitchell, P., Roy, K., & Hadzi-Pavlovic, D. (1999). Subytping depression: Testing algorithms and identification of a tiered model. Journal of Nervous and Mental Disease, 187, 610- 617. doi:10.1097/00005053-199910000-00004
Perry, P.J. (1996). Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders, 39, 1-6. doi:10.1016/0165-0327(96)00014-6
Porter, R., Gallagher, P., Thompson, J., & Young, A. (2003). Neuro-cognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry, 182, 214-220. doi:10.1192/bjp.182.3.214
Quera-Salva, M.A., Hajak, G., Philip, P., Montplaisir, J., Keufer-Le Gall, S., Laredo, J., & Guilleminault, C. (2011). Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology, 26, 252-262.doi:10.1097/YIC.0b013e328349b117
Racagni, G., Riva, M.A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., & Tardito, D. (2011). Mode of action of agomelatine: Synergy between melatonergic and 5-HT2c receptors. The World Journal of Biological Psychiatry, 12, 574-587. doi:10.3109/15622975.2011.595823
Raskin, J., Wiltse, C.G., Siegal, A., Javaid, S., Xu, J., Dinkel, J.J., Rotz, B.T., & Mohs, R.C. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. American Journal of Psychiatry, 164, 900-909. doi:10.1176/appi.ajp.164.6.900
Sheehan, D.V., Harnett-Sheehan, K., & Raj, B.A. (1996). The measurement of disability. International Clinical Psychopharmacology, 11, 89-95. doi:10.1097/00004850-199606003-00015
Silverstone, P.H., Entsuah, R., & Hackett, D. (2002). Two items on the Hamilton Depression rating scale are effective predictors of remis- sion: Comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. International Clinical Psychopharmacology, 17, 273-280. doi:10.1097/00004850-200211000-00002
Snaith, R.P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P.(1995). A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. British Journal of Psychiatry, 67, 99-103. doi:10.1192/bjp.167.1.99
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., & Mendlewicz, J. (2007). Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. Journal of Clinical Psychiatry, 68, 1062-1070. doi:10.4088/JCP.v68n0713
Stahl, S.M., Fava, M., Trivedi, M.H., Caputo, A., Shah, A., & Post, A. (2010). Agomelatine in the treatment of major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 71, 616-626. doi:10.4088/JCP.09m05471blu
Stein, D.J., Ahokas, A.A., & de Bodinat, C. (2008). Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 561-566. doi:10.1097/JCP.0b013e318184ff5b
Stein, D.J., & Kennedy, S.H. (2011). Efficacy of the novel antide- pressant agomelatine for anxiety symptoms within depression. Euro- pean College of Neuropsychopharmacology Annual Meeting, Paris, 5 September 2011.
Uher, R., Farmer, A., Maier, W., Rietschel, M., Hauser, J., Marusic, A., Mors, O., Elkin, A., Williamson, R.J., Schmael, C., Henigsberg, N., Perez, J., Mendlewicz, J., Janzing, J.G., Zobel, A., Skibinska, M., Kozel, D., Stamp, A.S., Bajs, M., Placentino, A., Barreto, M., Mc-Guffin, P., & Aitchison, K.J. (2008). Measuring depression: Com- parison and integration of three scales in the GENDEP study. Psychological Medicine, 38, 289-300. doi:10.1017/S0033291707001730
Uher, R., Maier, W., Hauser, J., Marusic, A., Schmael, C., Mors, O., Henigsberg, N., Souery, D., Placentino, A., Rietschel, M., Zobel, A., Dmitrzak-Weglarz, M., Petrovic, A., Jorgensen, L., Kalember, P., Giovannini, C., Barreto, M., Elkin, A., Landau, S., Farmer, A., Aitchison, K.J., & McGuffin, P. (2009). Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry, 194, 252-259. doi:10.1192/bjp.bp.108.057554
Wade, A.G., Fernández, J.L., Fran?ois, C., Hansen, K., Danchenko, N., & Despiegel, N. (2008). Escitalopram and duloxetine in major depressive disorder: A pharmacoeconomic comparison using UK cost data. Pharmacoeconomics, 26, 969-981. doi:10.2165/00019053-200826110-00008
Waldinger, M.D., Zwinderman, A.H., & Olivier, B. (2003). Antide-pressants and ejaculation: A double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. Journal of Clinical Psychopharmacology, 23, 467-470. doi:10.1097/01.jcp.0000088904.24613.e4
Warden, D., Trivedi, M. H., Wisniewski, S. R., Davis, L., Nierenberg, A. A., Gaynes, B. N., & Rush, A. J. (2007). Predictors of attrition during initial (citalopram) treatment for depression: A STAR*D report. American Journal of Psychiatry, 164, 1189-1197. doi:10.1176/appi.ajp.2007.06071225
Zajecka, J., Schatzberg, A., Stahl, S., Shah, A., Caputo, A., & Post, A. (2010). Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 30, 135-144. doi:10.1097/JCP.0b013e3181d420a7
Zigmond, A.S., & Snaith, R.P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361-370. doi:10.1111/j.1600-0447.1983.tb09716.x
Zimmerman, M., Ruggero, C.J., Chelminski, I., Young, D., Posternak, M.A., Friedman, M., Boerescu, D., & Attiullah, N. (2006). Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life. Journal of Clinical Psychiatry, 67, 1536-1541.doi:10.4088/JCP.v67n1007